ENSC Company Profile and Key Details

Q: Who are the executives of ENSC?

Mr. David C. Humphrey C.P.A.Chief Financial Officer, Sec. & TreasurerMr. David C. Humphrey CPAChief Financial Officer, Sec. & TreasurerDr. Jeffrey Millard Ph.d.Chief Operating OfficerMr. Richard Wright M.B.A., MSEChief Bus. OfficerDr. Linda Pestano Ph.D.Chief Devel. OfficerDr. William K. Schmidt Ph.D.Chairman of Clinical Advisory Board & Chief Medical OfficerDr. D. Lynn Kirkpatrick Ph.D.Pres, Chief Executive Officer & DirectorMr. Geoffrey BirkettChief Commercial Officer

NASDAQ : ENSC

Ensysce Biosciences

$0.61

0.0626+11.44%

At Close 4:00 PM

68.03

BESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Ensysce Biosciences, Inc. (ENSC) stock surged +11.44%, trading at $0.61 on NASDAQ, up from the previous close of $0.55. The stock opened at $0.54, fluctuating between $0.52 and $0.61 in the recent session.

Stock Snapshot

0.547

Prev. Close

1.56M

Market Cap

0.5201

Day Low

-0.15

P/E Ratio

-3.98

EPS (TTM)

-4.76

Cash Flow per Share

0.54

Open

2.56M

Number of Shares

0.6096

Day High

107.41%

Free Float in %

-0.29

Book Value

196.27K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Apr 02, 2026	0.54	0.61	0.52	0.61	207.83K
Apr 01, 2026	0.53	0.57	0.53	0.55	214.24K
Mar 31, 2026	0.50	0.56	0.49	0.54	415.08K
Mar 30, 2026	0.54	0.54	0.50	0.51	171.27K
Mar 27, 2026	0.54	0.56	0.48	0.53	351.06K
Mar 25, 2026	0.55	0.58	0.54	0.56	168.87K
Mar 24, 2026	0.57	0.57	0.53	0.55	164.82K
Mar 23, 2026	0.57	0.59	0.52	0.59	422.52K
Mar 20, 2026	0.56	0.60	0.53	0.58	571.51K
Mar 19, 2026	0.59	0.61	0.52	0.58	1.35M
Mar 18, 2026	0.48	0.65	0.45	0.63	6.33M
Mar 17, 2026	0.43	0.48	0.43	0.48	293.55K
Mar 16, 2026	0.42	0.44	0.40	0.43	320.26K
Mar 13, 2026	0.45	0.46	0.41	0.41	278.22K
Mar 12, 2026	0.45	0.46	0.42	0.43	320.7K
Mar 11, 2026	0.49	0.50	0.43	0.46	644.08K
Mar 10, 2026	0.52	0.53	0.49	0.49	532.69K
Mar 09, 2026	0.53	0.55	0.51	0.54	377.73K
Mar 06, 2026	0.51	0.55	0.49	0.55	677.75K
Mar 03, 2026	0.58	0.58	0.49	0.51	1.82M

Contact Details

La Jolla, CA 92037

United States

https://www.ensysce.com 858 263 4196

About Company

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.

Stock Peers

REGN

-15.4-1.98%

Regeneron Pharmaceuticals, Inc.$761.85 ARGX

3.3+0.44%

argenx SE$746.42 UTHR

-5.46-0.96%

United Therapeutics Corporation$564.81 MDGL

17.05+3.22%

Madrigal Pharmaceuticals, Inc.$546.89 VRTX

-8.55-1.91%

Vertex Pharmaceuticals Incorporated$438.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 ALNY

-9.88-3.01%

Alnylam Pharmaceuticals, Inc.$318.85 PRAX

-8.9-2.79%

Praxis Precision Medicines, Inc.$310.38 KRYS

2.04+0.79%

Krystal Biotech, Inc.$260.95 ASND

1.01+0.44%

Ascendis Pharma A/S$229.25

Company Overview

Ensysce Biosciences, Inc. (NASDAQ:ENSC) closed at $0.61 USD, gaining $0.06 (11.44%) from the previous close of $0.55. The stock is currently mid-range between its 52-week high and low $0.31 and $4.85. With a market capitalization of about $1.56 million, Ensysce Biosciences, Inc. is classified as a micro-cap and shows market-like volatility (beta ~1.16). Key stats such as the average daily volume over the past year has been around 6.02 million shares, volume is running light vs its 52-week average. Headquartered in La Jolla, CA, Ensysce Biosciences, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO D. Lynn Kirkpatrick, the company employs approximately 7 people and listed since March 14, 2018. Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States.

Technical Performance

ENSC has shown mixed momentum, gaining 3.75% over the past week and -60.55% over the past quarter, though year-to-date performance is up 2.07%. Short-term trend indicators are bullishly aligned (SMA20 -18.87%, SMA50 -50.29%, SMA200 -77.96%). The stock’s 14-day RSI is 30.24 (weak momentum), while the ATR of 0.09 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -93.09% below its high and over 25.64% above its low. Average 10-day trading volume of 254.73 thousand shares is below the 3-month average of 5.93 million, indicating normal recent market interest.

Valuation Metrics

Ensysce Biosciences, Inc. trades at a P/E ratio of -0.15, slightly below the S&P 500 average, with a price-to-sales ratio of 0.49 and a price-to-book ratio of 0.49 suggesting the stock is closer to book value. The P/FCF stands at -0.2, also above market averages.

Dividend & Fair Value

Ensysce Biosciences, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.83. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

The latest quarter delivered EPS of -$1.29. The next quarter is forecast at -$1.26. Next year's EPS is expected at $40.44. Ensysce Biosciences, Inc. earnings surprise history is a mixed track record. The quarter that ended November 14, 2025, missed forecasts by 51.76%. The prior quarter beat by -22.55%. Over the last six quarters, Apple has recorded several small beats. These include -43.59% in August 14, 2024.

Shareholding & Insider Activity

Ensysce Biosciences, Inc. has 2.37 million shares outstanding. The public float is 2.55 million shares, elevated short interest at 5.79% of float. This equals 135.76 thousand shares. The short ratio is 0.18 days. Institutional investors hold 6.06% of the float. Insiders own 0.35%. HG Vora Capital Management, LLC holds 3.84 million shares, GOWER BOB G has 1.22 million shares and Kirkpatrick Lynn has 381.85 thousand shares.

Financial & Profitability Overview

Over the trailing twelve months, Ensysce Biosciences generated $2.23M in revenue, or $0.99 per share. Gross margin was -240.17%, operating margin -480.52%, and net profit margin -476.39%. Returns are negative, with ROA at -392.38% and ROE at 1631.59%.
On valuation metrics, Ensysce Biosciences trades at a P/E of -0.15, P/S of 0.49 and P/B of 0.49. The current ratio is 1.59 and quick ratio is 1.59. Operationally, the company’s inventory turnover is 0.00 and cash conversion cycle is -196.34 days , indicating it collects cash faster than it pays suppliers. Debt-to-equity is 95437.06, supported by a cash flow-to-debt ratio of -0.00.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2023, Ensysce Biosciences posted revenue of $2.23M, down slightly from $0.00 in the prior quarter. Gross profit was - $5.36M (margin -240.17%). Operating income was - $10.72M (margin -480.5%). Net income was- $10.63M (EPS - $4.69).
The company ended the quarter with $1.12M in cash and short-term investments, a total debt of $854.70K, and net debt of - $268.91K. Total assets were $2.71M, with equity of - $979.68K. Financials further reflected weakness, with operating cash flow of - $10.78M, free cash flow of - $10.78M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Ensysce Biosciences, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 0.07%, with price expected at $0.61 by April 16, 2026, within a range of $0.52 to $0.69 3-Month Outlook: Projected fall of -78.67%, reaching $0.13 by July 01, 2026, with a range of $0.00 to $0.34. 1-Year Outlook: Projected loss of -80.31%, with price at $0.12 by April 02, 2027, within a range of $0.00 to $1.00.

Key Takeaways

Ensysce Biosciences, Inc. (NASDAQ:ENSC) shares are flat 2.07% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Ensysce Biosciences, Inc. trading at a premium to the broader market with a P/E of -0.15. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $7.50, suggesting 1130.31% upside. Our AI forecast model points to short-term strength (0.07% over two weeks), a medium-term fall (-78.67% over three months), and a longer-term loss (-80.31% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Ensysce Biosciences, Inc. (ENSC) stock price?

Ensysce Biosciences, Inc. (NASDAQ: ENSC) stock price is $0.61 in the last trading session. During the trading session, ENSC stock reached the peak price of $0.61 while $0.52 was the lowest point it dropped to. The percentage change in ENSC stock occurred in the recent session was 11.44% while the dollar amount for the price change in ENSC stock was $0.06.

ENSC's industry and sector of operation?

The NASDAQ listed ENSC is part of Biotechnology industry that operates in the broader Healthcare sector. Ensysce Biosciences, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ENSC?

Mr. David C. Humphrey C.P.A.
Chief Financial Officer, Sec. & Treasurer
Mr. David C. Humphrey CPA
Chief Financial Officer, Sec. & Treasurer
Dr. Jeffrey Millard Ph.d.
Chief Operating Officer
Mr. Richard Wright M.B.A., MSE
Chief Bus. Officer
Dr. Linda Pestano Ph.D.
Chief Devel. Officer
Dr. William K. Schmidt Ph.D.
Chairman of Clinical Advisory Board & Chief Medical Officer
Dr. D. Lynn Kirkpatrick Ph.D.
Pres, Chief Executive Officer & Director
Mr. Geoffrey Birkett
Chief Commercial Officer

How ENSC did perform over past 52-week?

ENSC's closing price is 94.14% higher than its 52-week low of $0.31 where as its distance from 52-week high of $4.85 is -87.43%.

How many employees does ENSC have?

Number of ENSC employees currently stands at 7.

Link for ENSC official website?

Official Website of ENSC is: https://www.ensysce.com

How do I contact ENSC?

ENSC could be contacted at phone 858 263 4196 and can also be accessed through its website. ENSC operates from 7946 Ivanhoe Avenue, La Jolla, CA 92037, United States.

How many shares of ENSC are traded daily?

ENSC stock volume for the day was 196.27K shares. The average number of ENSC shares traded daily for last 3 months was 6.02M.

What is the market cap of ENSC currently?

The market value of ENSC currently stands at $1.56M with its latest stock price at $0.61 and 2.56M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	7
Beta	1.16
Sales or Revenue	$2.23M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

ENSC Company Profile and Key Details

Ensysce Biosciences

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Key Takeaways

Price Forecast & Outlook